Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tumoral resistance to immune rejection. In humans, constitutive expression of IDO1 has been observed in several tumor types. However, a comprehensive analysis of its expression in normal and tumor tissues is still required to anticipate the risks and potential benefits of IDO1 inhibitors. Using a newly validated monoclonal antibody to human IDO1, we performed an extensive immunohistochemical analysis of IDO1 expression in normal and tumor tissues. In normal tissues, IDO1 was expressed by endothelial cells in the placenta and lung and by epithelial cells in the female genital tract. In lymphoid tissues, IDO1 was expressed in mature dendritic cells with a phenotype (CD83+, DC-LAMP+, langerin-, CD123-, CD163-) distinct from plasmacytoid dendritic cells. Importantly, IDO1-expressing dendritic cells were not enriched in tumor-draining lymph nodes, in contrast with previously reported findings. IDO1-expressin... The Cancer Genome Atlas database. Our observations indicate that the relevant IDO1 for tumoral immune escape is expressed in the tumor itself rather than in its draining lymph node.
Introduction
Tryptophan-2,3 dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) are the two main enzymes that catalyze the first and rate-limiting step in the kynurenine pathway leading to the degradation of the essential amino acid tryptophan (1) . TDO2 is expressed constitutively in the liver where it acts as the main regulator of systemic tryptophan levels.
The non-homologous IDO1 enzyme is expressed in the placenta and in mucosal and lymphoid tissues, as well as in inflammatory lesions (2, 3) . In the latter two, it seems to be principally expressed by antigen-presenting cells, mainly dendritic cells and macrophages, and in cells exposed to interferon-gamma (IFN-γ) and other pro-inflammatory stimuli. Local IDO1-mediated degradation of tryptophan is thought to reduce the bioavailability of this amino acid for pathogens, thus contributing to protection against infection (4) . It also appears to have a profound influence on local innate and adaptive immune responses (5) . T cells exposed to tryptophan depletion activate GCN2 kinase, a sensor of amino acid shortage that induces a stress response, resulting in impaired T cell proliferation and effector functions. In addition, tryptophan catabolites such as kynurenine downregulate T cell responses by interfering with DC function and by promoting regulatory T cell differentiation and apoptosis of CD4 + T helper 1 (Th1) cells (5, 6) . These observations indicate that IDO1 orchestrates a local immunosuppressive environment, presumably aimed at preventing exaggerated T cell responses. IDO1 knock-out mice, however, do not show signs of overt autoimmunity, indicating that IDO1 biology remains incompletely understood (7, 8) .
The immunosuppressive effect of IDO1 was originally demonstrated in a mouse model of fetal protection against maternal immune rejection. Treatment of pregnant mice with a tryptophan analog that inhibits IDO1, which is constitutively expressed in the placenta, resulted in T-cell mediated rejection of allogeneic embryos (9) . We extended this concept to malignant diseases by showing that mouse tumor cells expressing IDO1 resisted immune rejection by immunized mice. In addition, we demonstrated that this inhibition could be partially reversed by pharmacological inhibition of IDO1. We further showed that IDO1 was constitutively expressed and enzymatically active in several human tumor cell lines. We raised a rabbit polyclonal antibody against IDO1 for immunohistochemistry, and showed immunoreactivity in various human tumors (10) .
Several mechanisms have been proposed to explain how IDO1 may favor tumor growth and survival. The immunosuppressive properties described above may protect the tumor against T cell-mediated destruction, either through the expression of IDO1 in the tumor environment itself, or in tumor-draining lymph nodes. Recently, a role for IDO1 in tumor resistance against immune checkpoint blockade has been demonstrated in a murine model (11) . In this by non-cancerous cells of the tumor stroma. IDO1 could also act in favor of tumors through a non immunological mechanism, as tryptophan-derived kynurenine was shown to promote tumor cell survival and motility through activation of the aryl hydrocarbon receptor (6) .
Independently from its catalytic potential, IDO1 was also shown in murine experiments to act as a signaling molecule in transforming growth factor-beta mediated immune suppression (12) . Altogether, these observations provide a strong rationale for the clinical development in oncology of drugs that inhibit IDO1 and more particularly its catalytic activity, alone or in combination with other immunotherapy approaches such as CTLA4 blocking agents (13) .
Such IDO1 inhibitors are currently in the early phases of clinical testing.
In order to identify the best candidate tumors for IDO1 inhibitory therapy and evaluate its risks, it is important to have a precise picture of the pattern of IDO1 expression and of the nature of IDO1-expressing cells in normal and tumoral human tissues. A lot of attention has been devoted to the study of IDO1 expression and function in dendritic cells (reviewed in (14) ). In inflamed and lymphoid tissues, they appear to be the main contributors of IDO1 expression. Mature myeloid DC are the most frequently cited (15) (16) (17) , but IDO1 expression has also been reported in plasmacytoid DC, immature DC and macrophages (18) (19) (20) . Several studies have shown that IDO1 + cells were more abundant in melanoma draining lymph nodes than in control lymph nodes, suggesting that IDO1 contributes to immune evasion, possibly by interacting with regulatory T cells (18, (21) (22) (23) (24) . However, this difference was not found in breast cancer (25) . IDO1 expression and enzymatic activity in the placenta are well established, but there is still controversy about the nature of the cells that express it. IDO1
immunoreactivity has been reported in either trophoblast cells, macrophages, mesenchymal or endothelial cells, depending on the study (3, (26) (27) (28) (29) (30) (31) . In human tumors, most published studies have focused on IDO1 expression and prognostic significance in individual tumor types. In general, IDO1 expression was associated with a less favorable prognosis, with more aggressive features of the tumor, and with reduced immune cell infiltration or increased numbers of regulatory T cells (reviewed in 32). Of note, many of these studies relied on a limited number of patient samples, the method used to assess IDO1 expression was different from one study to the other, and the proportion of positive tumors as well as the nature of the IDO1-expressing cells were not always consistent (Supplementary Table ST1 ).
In summary, our current knowledge of IDO1 expression in normal and tumoral human tissues is incomplete, and several inconsistencies appear when the results of different studies are compared. It is likely that experimental differences and more particularly the diversity and 
Materials and methods

Patients and tissue samples
Normal tissue samples were obtained from routine biopsy, surgical resection, autopsy or obstetrical material. All cases were verified histologically to ensure that no lesion was present. The clinical characteristics of the patients from whom tumor-draining lymph nodes were obtained are summarized in Supplementary Table ST2 . Tissue microarrays (TMAs)
were constructed from formalin-fixed paraffin-embedded (FFPE) archived tumor pathology specimens. Briefly, 3 or 5-mm cores were taken in tumor areas identified on hematoxylineosin stained sections, using a manual arrayer (Quick-Ray™, Unitma 
Plasmid constructs and cell transfectants
The complete IDO1 coding sequence was amplified from human placenta RNA by RT-PCR using sense primer 5'-GAGGAGCAGACTACAAGAATG-3' and antisense primer 5'-GCATACAGATGTCTCTGCTATG-3'. The PCR product was cloned into pEF6/V5-His TOPO (Invitrogen) and verified by DNA sequencing. 293-EBNA cells (Invitrogen) were transfected by electroporation with the IDO1-expressing plasmid, and transfectants were selected with 5 g/ml blasticidin and 400 M 1-methyl-DL-tryptophan (Sigma-Aldrich).
Clones obtained by limiting dilution were amplified in the presence of 1-methyl-DLtryptophan.
To prepare an immunogen for antibody generation, the DNA sequence encoding the first 161 amino acid of human IDO1 was amplified by PCR from the full length IDO1 cDNA with primers 5'-CAGACTTCTAGAATGGCACACGCTATG-3' and 5'-GACCAGGGCGGCCGCTTTACTGCAGTCTCCATC-3'. The PCR product was inserted into the pCD1 expression vector, downstream of the human CD134L coding sequence (33, 34) . The plasmid construct, which encodes the CD134L-hIDO1 1-161 fusion protein, was verified by sequencing.
Western blotting
Cell pellets were lysed in lysis buffer (Cytobuster™, Novagen), and centrifuged for 5 min at Figure S2) .
Computerized sequential immunohistochemistry for double stainings (CsIHC)
Tissues were processed using the same pre-incubation steps as for normal tissues except that by immersing slides into ethanol, followed by blockade of non-specific binding and incubation with our anti-IDO1 polyclonal rabbit antibody, as described above. IDO-1 was revealed in brown using EnVision™ and DAB, and images were captured at spatial coordinates recorded previously thereby producing a set of strictly superimposable pictures.
The inverse of the FastRed and DAB monochrome images were used as red and green channels of a new pseudocolor picture. 
Quantitative analysis of IDO1 staining in tumor-draining lymph nodes
Staining for IDO1 was quantified on slides without counterstaining with the ImageJ software (http://rsb.info.nih.gov//ij/). Five digitalized pictures were obtained for each case in fields containing the highest proportions of stained cells (hot spots). The relative stained area was determined by calculating the ratio of surface staining for IDO1 to the overall surface.
In vitro generation of monocyte-derived DCs
Peripheral blood mononuclear cells were isolated from buffy-coat collections obtained from hemochromatosis patients, and purified by density gradient centrifugation on Lymphoprep (Axis-Shield). Monocytes were isolated using anti-CD14-coated microbeads (Miltenyi Biotec), and were differentiated in vitro to immature DC (iDC) during 5 days in RPMI medium supplemented with 10% fetal calf serum,
, 70 ng/ml granulocyte-macrophage colony-stimulating-factor and 20 U/ml interleukin-4. iDC were matured during 2 days with IFN-γ (500 U/ml), lipopolysaccharide (LPS) (100 ng/ml), prostaglandin-E2 (PGE2, 1 µg/ml), interleukin-1-beta (IL-1β, 10 ng/ml), interleukin-6 (IL-6, 25 ng/ml) and tumor-necrosis factor-alpha (TNF-α, 10 ng/ml).
Flow cytometry
Dendritic cells were stained with fluorescent conjugated antibodies specific for CD11c (clone 
Cytokine measurement
Monocytes were cultured in growth medium as described. At day 6, 100 ng/ml LPS (SigmaAldrich) were added to the iDC. Cytokine release was measured in the supernatant with Cytometric Beads array kit on a Bio-Plex instrument (Bio-Rad Laboratories). 
IDO1 activity
T cell proliferation assays
For the CD4 + T cell proliferation assay (Supplementary Figure S3) , monocyte-derived DC were prepared as described above. Supernatants were collected after 48 hours. CD4 + lymphocytes were sorted using anti-CD4 microbeads (Miltenyi Biotec). The CD4 + cells (2x10 5 cells/well) were resuspended in 100 µl of tryptophan-depleted DMEM medium (Gibco) and mixed with 100 µl of conditioned DC medium. They were activated in 96 well plates coated with anti-CD3 antibody (10 µg/ml). After 3 days, proliferation was assessed by
[3H]-thymidine (10 µCi/w in HBSS) uptake overnight. Each condition was tested in triplicate. For the inhibitory assay (Supplementary Figure S4) , DC matured with 100 ng/ml LPS and 250 U/ml IFN-γ were used to stimulate peripheral blood mononuclear cells in the presence of the indicated tryptophan analogs. Each condition was tested in duplicate.
Proliferation was measured after 5 days by [H 3 ]-thymidine uptake.
The Cancer Genome Atlas (TCGA) data mining
Normalized total mRNA counts for main tumor types were derived from whole transcriptome datasets generated by the TCGA 
Results
Production and validation of a murine monoclonal antibody directed at human IDO1
Balb/c mice were immunized with P815 mouse mastocytoma cells transfected with a CD134L-hIDO1 Figure S1A) . We conclude that the 4.16H1 mAb recognizes the human IDO1 protein specifically.
IDO1 expression in normal tissues
Although the expression and enzymatic activity of IDO1 in human placenta are well established, there is controversy about its cellular localization. When we stained placental tissue sections with the 4.16H1 antibody, only endothelial cells and some mesenchymal cells were positive ( Figure 1A ). We found no expression in the trophoblast of term placenta. To confirm endothelial expression, we performed computerized sequential IHC (CsIHC) using IDO1 and CD31 antibodies on the same tissue section ( Figure 1A , inset). This method was chosen because the 4.16H1 antibody works best with paraffin-embedded sections, which are not optimal for double staining by immunofluorescence. We next tested a large series of normal human tissues by IHC using our validated antibody (Table 1) . Consistent with previous reports (29) , IDO1 was detected in some scattered cells in the glandular epithelium of the female reproductive tract, and in lymphoid organs including lymph nodes, spleen, tonsils, Peyer's patches, the gut lamina propria and the thymus (Figure 1 B-F) . In lymph nodes, tonsils and Peyer's patches, IDO1 staining was mainly observed in paracortical T cell areas ( Figure 1B ), in cells that were larger than lymphocytes and tended to have an irregular outline compared to lymphocytes (often stellate cells with ramified cytoplasmic expansions, Figure 1C ). The spleen contained numerous IDO1-expressing cells in periarteriolar _______ 18/07/14 lymphocyte sheaths and some scattered positive cells in the Billroth's cords ( Figure 1D ). The lamina propria of the duodenum, small and large intestine contained interstitial mononuclear IDO1-positive cells, which were larger than lymphocytes ( Figure 1E ). CsIHC for IDO1 and DC-LAMP showed that most (>50%) of these cells were mature DCs (data not shown). In the thymus, the expression of IDO1 was restricted to the medulla ( Figure 1F ). Numerous interstitial cells, morphologically different from lymphocytes, were strongly positive whereas a weak positivity was observed in rare epithelial cells including Hassal's bodies, as confirmed by CsIHC for IDO1 and cytokeratin ( Figure 1F, inset) . In the bone marrow, we only observed a weak IDO1 expression in very few cells, which could correspond to some stromal or dendritic cells (data not shown). In non-lymphoid organs, IDO1 + cells were consistently observed within interstitial lymphocyte aggregates (data not shown). IDO was also detected in endothelial cells of many blood vessels in the lung alveolar tissue (Supplementary Figure   S2 ), and of a few blood vessels in prostate, uterus and urothelium (data not shown). IDO1
was recently reported to be expressed at high levels in mouse epididymis (35) . We observed no staining in human epididymis (Table 1) , and we confirmed the lack of expression of the IDO1 gene by RT-qPCR in two human epididymis samples (data not shown).
Characterization of IDO1-positive cells in normal lymph nodes
In lymph nodes, the morphology of 
Characterization of IDO1-positive cells in tumor-draining lymph nodes
To verify previously published results showing that IDO1 + cells were more abundant in tumor-draining lymph nodes (TDLN) than in control lymph nodes (21), we repeated the analysis with our 4.16H1 antibody. We selected TDLN from 15 melanoma and 15 breast carcinoma patients, whose characteristics are described in Supplementary Table ST2 , and are comparable with previously reported work (21) . IDO1 + cells were present, but their number have resulted from lack of specificity of the antibody used. In fact, some of these studies used antibody AB5968, which we found to be cross-reactive (Supplementary Figure S1 ) (18, 21, 22) .
Expression of IDO1 by in vitro-derived DC
Since lymph nodes contain IDO1 + mature dendritic cells, we tested whether human dendritic cells derived in vitro from monocytes also express IDO1 upon maturation. Monocyte-derived dendritic cells were matured using either LPS or a cocktail of IL-1ß, IL-6, TNF- and PGE2, commonly used to produce DC vaccines for clinical immunotherapy. As reported previously by others, iDC did not express IDO1 whereas both types of mature DC did (Supplementary Figure S3A) . The latter were able to degrade tryptophan and produce kynurenine, indicating that IDO1 was functional in these mature DC (Supplementary Figure S3B) . This activity was blocked by 1-methyl-L-tryptophan, a known IDO1 inhibitor, and not by its enantiomer 1-methyl-D-tryptophan, confirming the lack of inhibition of IDO1 by the latter (36,37). When we added mature DC-conditioned medium to CD4 + T cells activated with coated anti-CD3
antibody, we observed that T cell proliferation was prevented, whereas it was maintained with the immature DC-conditioned medium (Supplementary Figure S3B) . This proliferation was In an effort to explain the paradoxical expression of IDO1, an immunosuppressive factor, in mature DC, which are supposed to effectively trigger immune responses, we considered that IDO1 induction might be a late step in the maturation program of dendritic cells, ensuring a negative feedback aimed at preventing excessive T cell activation. We conducted a detailed kinetic study of DC maturation by LPS, monitoring the acquisition of maturation markers, the production of stimulatory cytokines, and the induction of IDO1 at the protein level (Supplementary Table ST3 
Frequency and pattern of expression of IDO1 in human tumors
We used IHC with our 4.16H1 antibody to assess IDO1 expression in 15 common solid tumor types. About 60 samples of each were investigated on TMA sections. In total, 383 of 882 tumors (43%) showed positive staining, often limited to a small number of cells (Table 2 and were often present at the outer limit of the tumor area in contact with stroma, whereas they were more diffusely distributed in endometrial tumors ( Figure 5A and B).
We confirmed the IHC screening data with IDO1 gene expression levels for each tumor type retrieved from the RNA-Seq data of The Cancer Genome Atlas (TCGA) public database. The This latter observation has already been questioned by others (39, 40) . RNA-Seq data (normalized total mRNA counts) from the indicated tumor types and numbers were retrieved from The Cancer Genome Atlas database and displayed as horizontal boxplot graphs, in which the vertical bars represent from left to right: lowest value (zero in all cases), first quartile, median, third quartile and highest value. Italicized tumor types were not investigated by immunohistochemistry, whereas stomach and esophageal carcinomas are not represented here. 
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